Get exclusive money-saving offers and guides
Straight to your inbox
By signing up, you agree to the Finder Privacy & Cookies Policy and Terms of Use, Disclaimer & Privacy Policy.
How to buy Pro Medicus shares
Own Pro Medicus shares in just a few minutes.
Posted
Fact checked
Investments
Pro Medicus Limited is a health information services business based in Australia. Pro Medicus shares (PME) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Pro Medicus has a trailing 12-month revenue of around $56.8 million.
How to buy shares in Pro Medicus
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Pro Medicus. Find the share by name or ticker symbol: PME. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pro Medicus reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Pro Medicus. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Pro Medicus share price
Use our graph to track the performance of PME stocks over time.Pro Medicus shares at a glance
Information last updated 2020-09-25.
| 52-week range | AUDA$14.5 - AUDA$32.14 |
|---|---|
| 50-day moving average | AUDA$25.5067 |
| 200-day moving average | AUDA$24.7116 |
| Target price | AUDA$9.96 |
| PE ratio | 118.8235 |
| Dividend yield | AUDA$0.12 (0.45%) |
| Earnings per share (TTM) | AUDA$0.221 |
Share Trading Account Offer
IG Share Trading Offer
AUD 8
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
More info
Important: Share trading carries risk of capital loss.
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Pro Medicus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Pro Medicus under- or over-valued?
Valuing Pro Medicus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pro Medicus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pro Medicus's P/E ratio
Pro Medicus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Pro Medicus shares trade at around 119x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pro Medicus's EBITDA
Pro Medicus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.9 million.
The EBITDA is a measure of a Pro Medicus's overall financial performance and is widely used to measure a its profitability.
Pro Medicus financials
| Revenue TTM | $56.8 million |
|---|---|
| Operating margin TTM | 52.91% |
| Gross profit TTM | $56.5 million |
| Return on assets TTM | 20.89% |
| Return on equity TTM | 42.16% |
| Profit margin | 40.61% |
| Book value | 0.579 |
| Market capitalisation | $2.9 billion |
TTM: trailing 12 months
Pro Medicus share dividends
Dividend payout ratio: 47.51% of net profits
Recently Pro Medicus has paid out, on average, around 47.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pro Medicus shareholders could enjoy a 0.45% return on their shares, in the form of dividend payments. In Pro Medicus's case, that would currently equate to about A$0.12 per share.
While Pro Medicus's payout ratio might seem fairly standard, it's worth remembering that Pro Medicus may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 9 September 2020 (the "ex-dividend date").
Pro Medicus share price volatility
Over the last 12 months, Pro Medicus's shares have ranged in value from as little as $14.5 up to $32.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pro Medicus's is 1.1072. This would suggest that Pro Medicus's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Pro Medicus overview
Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.
Frequently asked questions
Ask an Expert